Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1618
This examiner grants 68% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18628570 | USE OF LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), AS AGENTS FOR THE TREATMENT OF PROSTATE CANCER | Final Rejection | NOVARTIS AG |
| 18440783 | LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) AS AGENTS FOR THE TREATMENT OF PROSTATE CANCER | Non-Final OA | NOVARTIS AG |
| 18754996 | SYNTHESIS OF THE RADIOLABELED PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITOR [18F]DCFPYL | Non-Final OA | The Johns Hopkins University |
| 16887704 | TAILORED DRUG DELIVERY VEHICLES FOR IN VIVO PROTECTION OF ANALYTE SENSING COMPOUNDS | Non-Final OA | Senseonics, Incorporated |
| 16545147 | MEDIATED DRUG RELEASE FOR REDUCING IN VIVO ANALYTE INDICATOR DEGRADATION | Non-Final OA | Senseonics, Incorporated |
| 18684103 | RADIOIMMUNOCONJUGATES TARGETING CALRETICULIN FOR USE IN THE TREATMENT OF CANCER | Non-Final OA | ACTINIUM PHARMACEUTICALS, INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy